Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Comvita Takes Remaining 50% Of Api-Med

Comvita Takes Remaining 50% Of Medical Honey Company Api-Med

AX-listed natural health products company Comvita announced today it has bought all the remaining shares in Cambridge-based Api-Med Medical Honey Limited.

One of Api-Med's UK customers recently received the European CE mark certification for its wound dressing products that will allow manuka honey dressings to be marketed directly to hospitals and clinics.

Comvita Chairman Bill Bracks in announcing full acquisition of Api-Med Honey Limited says the original 50% shareholding purchased in September was largely undertaken to secure the intellectual property for manufacturing wound dressings that are infused with high UMF manuka honey.

"The purchase of the remaining 50% of the company is a practical move that allows Comvita to add value to the company through entering new ethical medical markets where New Zealand's indigenous manuka honey has been embraced as a leading edge method of treating wounds and serious ulcers. It is a major step for the company by taking a position at the medical end of the health continuum.

Comvita's chief executive Graeme Boyd says the use of honey products in medical situations opens exciting new market potential for Comvita and New Zealand plus opening new economic opportunities for beekeepers and landowners.

Boyd says uses such as wound dressings add value to a natural resource and offer huge growth potential in international markets.

Api-Med is involved in clinical trials with the Auckland University's Clinical Trials Unit beginning in January.

Graeme Boyd says there is a large body of research now available on the antibacterial activity of manuka honey and of its rapid healing characteristics, spearheaded by Dr Peter Molan of Waikato University.

He says the clinical trials will provide the final level of certainty needed to take the products in to the medical field.

"We have long recognised there is solid revenue potential in the medical area for natural products companies that have strong research capabilities. We have been steadily working toward that goal of entering that market."

The Api-Med purchase is in line with the strategic focus of Comvita to be a leading player in wellness products through a genuine and resourced innovation programme. The purchase and clinical trials are part of a planned process of growth for the company.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Stats NZ: Consents For New Homes At All-Time High

A record 41,028 new homes have been consented in the year ended March 2021, Stats NZ said today. The previous record for the annual number of new homes consented was 40,025 in the year ended February 1974. “Within 10 years the number of new homes ... More>>

Stats NZ: Unemployment Declines As Underutilisation Rises

The seasonally adjusted unemployment rate decreased to 4.7 percent in the March 2021 quarter, continuing to fall from its recent peak of 5.2 percent in the September 2020 quarter but remaining high compared with recent years, Stats NZ said today. ... More>>


Digitl: The Story Behind Vodafone’s FibreX Court Ruling

Vodafone’s FibreX service was in the news this week. What is the story behind the Fair Trading Act court case? More>>

Reserve Bank: Concerned About New Zealand's Rising House Prices

New Zealand house prices have risen significantly in the past 12 months. This has raised concerns at the Reserve Bank of New Zealand – Te Putea Matua about the risk this poses to financial stability. Central banks responded swiftly to the global ... More>>

Westpac: Announces Strong Financial Result

Westpac New Zealand (Westpac NZ) [i] says a strong half-year financial result has been driven by better than expected economic conditions. Chief Executive David McLean said while the global COVID-19 pandemic was far from over, the financial effect on ... More>>

MYOB: SME Confidence In Economic Performance Still Cautious

New insights from the annual MYOB Business Monitor have shown the SME sector is still cautious about the potential for further economic recovery, with two-in-five (41%) expecting the New Zealand economy to decline this year. The latest research ... More>>